Spain Insulin Drugs And Delivery Devices Market Size (2024 - 2029)

The Spain Insulin Drugs and Delivery Devices Market is experiencing growth, driven by the increased focus on managing diabetes, particularly in the context of COVID-19. The pandemic underscored the heightened risks for individuals with diabetes, prompting a greater emphasis on diabetes care and management. This situation has led to expanded opportunities for innovation in diabetes care delivery, such as virtual consultations and advanced diabetes technology, which have contributed to the market's expansion.

Home Market Analysis Healthcare Research Device Drug Combination Research Diagnostics and Therapeutics Research Diabetes Care Research Insulin Drugs And Delivery Devices Market in Spain Market Size

Market Size of Spain Insulin Drugs And Delivery Devices Industry

Spain Insulin Drugs And Delivery Devices Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2018 - 2022
CAGR 1.80 %

Major Players

Spain Insulin Drugs And Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Spain Insulin Drugs And Delivery Devices Market Analysis

The Spain Insulin Drugs and Delivery Devices Market size is estimated at USD 0.35 billion in current year, and is expected to reach USD 0.38 million by forecast year, growing at a CAGR of 1.80% during the forecast period.

One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic. That's why managing or delaying cases of type 2 diabetes became more important than ever before. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.

The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the insulin market's growth.

Spain Insulin Drugs And Delivery Devices Industry Segmentation

Insulin is mainly used to treat type 1 diabetes but can also be used in people with type-2 diabetes if insulin levels remain low despite using other medications. There are different ways to inject insulin into a patient's body using syringes, pens, pumps, and jet injectors, giving them various options for insulin delivery. The Spain Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins) and Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD) and volume (in mL) for insulin drugs and (in unit) for the devices for the above segments.

Drug
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Device
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Need A Different Region Or Segment?
Customize Now

Spain Insulin Drugs And Delivery Devices Market Size Summary

The Spain insulin drugs and delivery devices market is poised for growth, driven by the increasing prevalence of diabetes and the rising demand for advanced diabetes management solutions. The COVID-19 pandemic has underscored the critical importance of managing diabetes, as individuals with this condition face heightened risks of severe complications from the virus. This has led to a greater emphasis on innovative diabetes care delivery methods, such as virtual consultations and advanced diabetes technologies, which have removed regulatory barriers and spurred market expansion. The market is characterized by a shift towards more sophisticated insulin delivery systems, such as insulin pumps, which offer continuous and precise insulin administration, reducing the need for traditional injection methods. These technological advancements are expected to capture a significant share of the market, particularly among individuals with type-1 diabetes, by providing near-physiological insulin delivery and improving overall glucose control.

The market landscape in Spain is moderately consolidated, with key players like Eli Lilly, Novo Nordisk, and Sanofi leading the charge in developing and commercializing insulin therapies and delivery devices. Collaborations and strategic alliances, such as those between Eli Lilly and Boehringer Ingelheim, and Novo Nordisk and Ypsomed, have strengthened market presence and facilitated the introduction of innovative solutions. The integration of diabetes prevention and treatment into primary health services, as recommended by the World Health Assembly, along with increased awareness and research collaborations, is expected to further drive market growth. The ongoing development and rollout of new products, coupled with the growing demand for effective diabetes management solutions, position the Spanish insulin drugs and delivery devices market for continued expansion in the coming years.

Explore More

Spain Insulin Drugs And Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Basal or Long-acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast-acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 2.1.2.2 Humalog (Insulin lispro)

        3. 2.1.2.3 Apidra (Insulin glulisine)

        4. 2.1.2.4 FIASP (Insulin aspart)

        5. 2.1.2.5 Admelog (Insulin lispro Sanofi)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Combination Insulins

        1. 2.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 2.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)

        3. 2.1.4.3 Xultophy (Insulin degludec and Liraglutide)

        4. 2.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)

      5. 2.1.5 Biosimilar Insulins

        1. 2.1.5.1 Insulin Glargine Biosimilars

        2. 2.1.5.2 Human Insulin Biosimilars

    2. 2.2 Device

      1. 2.2.1 Insulin Pumps

        1. 2.2.1.1 Insulin Pump Devices

        2. 2.2.1.2 Insulin Pump Reservoirs

        3. 2.2.1.3 Insulin Infusion sets

      2. 2.2.2 Insulin Pens

        1. 2.2.2.1 Cartridges in reusable pens

        2. 2.2.2.2 Disposable insulin pens

      3. 2.2.3 Insulin Syringes

      4. 2.2.4 Insulin Jet Injectors

Spain Insulin Drugs And Delivery Devices Market Size FAQs

The Spain Insulin Drugs and Delivery Devices Market is projected to register a CAGR of 1.8% during the forecast period (2024-2029)

Eli Lilly, Novo Nordisk, Sanofi, Ypsomed and Medtronic are the major companies operating in the Spain Insulin Drugs and Delivery Devices Market.

Spain Insulin Drugs And Delivery Devices Market Report Snapshots

Spain Insulin Drugs and Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)